Belagenpumatucel-L

Drug Profile

Belagenpumatucel-L

Alternative Names: Glionix; Lucanix; Ranagengliotucel-T; TGF-beta2 antisense gene modified allogeneic tumour cell vaccine - NovaRx

Latest Information Update: 19 Aug 2016

Price : $50

At a glance

  • Originator Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Developer NovaRx Corporation
  • Class Antisense DNA; Cancer vaccines; Cell therapies; Tumour cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Glioma; Non-small cell lung cancer

Most Recent Events

  • 19 Aug 2016 NovaRx intends to initiate new clinical studies for Belagenpumatucel-L, either as monotherapy or combination therapy
  • 15 Mar 2016 Biomarkers information updated
  • 28 Sep 2013 Efficacy data from a phase III trial in Non-small cell lung cancer presented at the European Cancer Congress 2013 (ECC-2013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top